Core Viewpoint - Botao Bio is forecasting a significant decline in net profit for 2025, with an expected net profit of approximately 45 million yuan, representing a year-on-year decrease of about 73.45% [1] Revenue Impact - The company's revenue is expected to be adversely affected in the first half of 2025 due to multiple tariff increases imposed by the U.S. government, leading to a decline in exports to the U.S. [1] - Domestic demand for respiratory testing products and mosquito-borne disease products in Latin America has also decreased year-on-year, further impacting overall revenue [1] Expense Impact - The company is focusing on innovation and team incentives, which has led to increased research and development expenses and costs associated with employee stock ownership plans [1] - Financial income from foreign exchange gains and interest has decreased year-on-year, contributing to a significant decline in profits [1] Non-Operating Income Impact - In the previous period, the company benefited from a $5 million advance payment and transportation fees from overseas customers for COVID-19 testing products, which were recognized as revenue in 2024, leading to increased net profit [1] - The current reporting period did not experience similar non-operating income, which has negatively affected profit figures [1]